Notably, NSCLC cells carrying KRAS G12D or BRAF V600E mutants were more sensitive to MEK inhibition than control GFP-transduced cells, as evidenced by partly restored MYC expression upon GC/G treatment compared to GC alone (Figure 6B, C). This evidence concerns the gene KRAS and non-small cell lung carcinoma.